SHARON BECK: Open Payments
NPI 1821161886 · WHEATON, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,122 in 43 payments from 14 companies in 2025. Trend: 2023 $593 · 2024 $1,005 · 2025 $1,122
Food & beverage: $1,122
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $278 |
| Neurocrine BioSciences, Inc. | 5 | $220 |
| Teva Pharmaceuticals USA, Inc. | 5 | $94 |
| Axsome Therapeutics, Inc. | 4 | $79 |
| Alkermes, Inc. | 3 | $68 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $67 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| Tris Pharma Inc | 3 | $54 |
| ABBVIE INC. | 3 | $52 |
| Corium, LLC | 2 | $49 |
Products named: INGREZZA, REXULTI, ARISTADA, CAPLYTA, UZEDY, ABILIFY ASIMTUFII, FANAPT, Dyanavel XR.
Industry payments across IL — which companies pay providers there.
